Study ID (Protocol Number)
CA180-226
 
STUDY LOCATIONS*


 




*Not all study site locations may be listed - please check back soon for updated
information. For more information regarding other participating countries, please
visit clinicaltrials.gov.
  STUDY NAME
A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to Imatinib
STUDY OVERVIEW
The purpose of this study is to determine whether dasatinib is safe and effective in children and adolescents with newly diagnosed chronic myeloid leukemia (CML), or in children with Ph+ acute lymphoblastic leukemia (ALL), accelerated or blast phases CML who relapse after imatinib or who are resistant or intolerant to imatinib. The side effects of this oral investigational drug in children and adolescents will be evaluated
 

 
The study information provided here is a portion of what is available on ClinicalTrials.gov. Please visit ClinicalTrials.gov for complete information about this and other clinical studies.
Find A Study